| Literature DB >> 32373485 |
Iti Chauhan1, Mohd Yasir2, Madhu Verma1, Alok Pratap Singh1.
Abstract
Nanostructured lipid carriers (NLCs) are novel pharmaceutical formulations which are composed of physiological and biocompatible lipids, surfactants and co-surfactants. Over time, as a second generation lipid nanocarrier NLC has emerged as an alternative to first generation nanoparticles. This review article highlights the structure, composition, various formulation methodologies, and characterization of NLCs which are prerequisites in formulating a stable drug delivery system. NLCs hold an eminent potential in pharmaceuticals and cosmetics market because of extensive beneficial effects like skin hydration, occlusion, enhanced bioavailability, and skin targeting. This article aims to evoke an interest in the current state of art NLC by discussing their promising assistance in topical drug delivery system. The key attributes of NLC that make them a promising drug delivery system are ease of preparation, biocompatibility, the feasibility of scale up, non-toxicity, improved drug loading, and stability.Entities:
Keywords: Lipid; Nanostructure lipid carrier; Skin; Topical
Year: 2020 PMID: 32373485 PMCID: PMC7191226 DOI: 10.34172/apb.2020.021
Source DB: PubMed Journal: Adv Pharm Bull ISSN: 2228-5881
Advantages and disadvantages of Nanostructured Lipid Carriers[5-7]
|
|
|
| More loading capacity for some drugs | Cytotoxic effects related to the nature of lipid matrix and concentration |
| Less water in the dispersion | Irritation and sensitizing action of surfactants |
| Prevent or minimize the drug expulsion during storage | Application and efficiency in case of protein and peptide drugs and gene delivery systems still need to be exploited |
| Control and targeted drug release | Stability of Lipids |
| Feasibilities of loading both lipophilic and hydrophilic drugs | - |
| Use of biodegradable and biocompatible lipids | - |
| Avoid organic solvents | - |
| More affordable (less expensive than polymeric/surfactant based carriers | - |
| Easier to qualify, validate and gain regulatory approval | - |
| Better physical stability | - |
| Ease of preparation and scale-up | - |
| Improve benefit/risk ratio | - |
| Increase of skin hydration and elasticity | - |
| Small size ensures close contact with the stratum corneum | - |
| Enhanced stability of drugs | - |
Figure 1Excipients used in formulating NLC[6,7,11]
|
|
|
| Solid lipid | Bees wax, Caranauba wax 2442, Stearic acid, Cetyl Palmitate, Apifil®, Cutina CP®, Dynasan® 116, Dynasan®118,Precifac ATO, Compritol®888 ATO, Elfacos® C 26, Imwitor 900®,Precirol® ATO 5, tristearin, cholesterol, Palmitic acid |
| Liquid lipids (oils) | Cetiol V, Miglyol® 812, Castor oil, oleic acid, Davana oil, Palm oil, Olive oil, Isodecyl oleate, Paraffin oil, propylene glycol dicaprylocaprate, linoleic acid, decanoic acid, Argan oil, coconut oil |
| Emulsifying agents |
Pluronic® F68 (poloxamer 188), Pluronic® F127 (poloxamer 407), Tween 20, Tween 40, Tween 80,polyvinyl alcohol, Solutol® HS15, trehalose, sodium deoxycholate, Sodium glycocholate, sodium oleate,polyglycerol methyl glucose distearate, Tego®Care 450, Tween™80, Maquat® SC 18Maquat® BTMC-85%, Egg lecithin, soya lecithin, phosphatidylcholines, phosphatidylethanolamines, |
| Counter-ions | Sodium hexadecyl phosphate, Monodecyl phosphate, Mono hexadecyl phosphate, Mono octyl phosphate, Dextran sulphate sodium salt, Hydrolysed and polymerised epoxidised soybean oil |
Figure 2
Figure 3Literature review of drugs incorporated into NLC to enhance stability
|
|
|
|
|
|
| Idebenone (IDB) | Modified high-shear homogenization and ultrasound method | Glyceryl palmito-stearate, Medium chain fatty acid triglycerides |
1. Medium chain fatty acid triglycerides as liquid lipid, possesses a higher solubility for IDB than solid lipids and is incorporated into the core of a solid lipid. The drug is probably in the liquid lipid which in turn is surrounded by the solid lipid. | 90 |
| Coenzyme Q10 (CoQ10) | Hot high pressure homogenization technique | O/020G, O/100G, Glycerin monostearate, Glyceride, Span 20 |
1. CoQ10 existed as amorphous form in the NLC-based formulation and showed considerably enhanced photo-stability compared with CoQ10 itself. | 57 |
| Alpha-lipoic acid (ALA) | Hot high pressure homogenization technique |
Glycerin monostearate, |
1. About 88.5% of the initial ALA in NLC system remained after 120 days under the same conditions, while the retention of free ALA was only 0.7% under natural daylight irradiation. | 91 |
| Retinyl Palmitate (RP) | Ultrasonication method | Stearic acid, cetyl palmitate, Virgin coconut oil |
1, NLC was found to be superior formulation to protect RP against stressed conditions of light, temperature and hydrolytic degradation. | 92 |
| Lutein | High pressure homogenization. |
Glyceryl tripalmitate, Carnauba wax |
1. NLC improved the lutein thermostability and photostability 10 times more than the free form. | 93 |
| Ascorbyl palmitate (AP) | High pressure homogenization technique | Imwitor® 900 (glyceryl monostearate), Labrafil® M1944 (apricot kernel oil polyethylene glycol-6 ester), Hydrine® (PEG-2 stearate), Apifil® (nonionic hydrophilic white beeswax) |
1. Choice of surfactant was one of the important factors to increase the stability of AP aligned at the interface. | 65 |
| Phenylethyl resorcinol (PR) | Hot high-pressure homogenization method. |
Glycerin monostearate, diglycerides, BehenylAlcohol |
1. In 90 days’ storage, 88.6 ± 2.8% of PR remained unchanged in PR-NLC under natural daylight. | 94 |
Literature review of drugs incorporated into NLC for prolonged release
|
|
|
|
|
|
| Aceclofenac |
Melt-emulsification and low-temperature solidification method | To formulate a controlled-release drug delivery system for a prolonged period to satisfy the goals of the treatment of arthritis like reducing pain and inflammation |
1. Oleic acid played an important role in the release of aceclofenac from the NLC dispersion. | 42 |
| Amoitone B | Emulsion-evaporation and low temperature-solidification technology | To construct an effective delivery system for Amoitone B to realize sustained release, thus prolong drug circulation time in body and improve the bioavailability. |
1. When contacting the release solution, the superficial drug was freed quickly, leading to the burst release in the initial stage. | 95 |
| Oridonin | Emulsion-evaporation and low temperature-solidification technique | To prepare oridonin-loaded NLC, in which the Nanoparticles can be obtained in mild conditions easily without the need of any special equipment and the sustained drug release can also be achieved. |
1. During emulsification, at first, most of the drug was dispersed in lipid droplets due to low solubility in water. | 96 |
Figure 4Patent status of NLC
|
|
|
|
|
|
| Novel nano-lipid carrier for injection embodying paclitaxel series substances and preparation method thereof | CN101366697A | Liu et al | 18/2/2009 | 98 |
| Nanostructured lipid carriers containing riluzole and pharmaceutical formulations containing said particles | EP20070764871 | Bondi et al | 20/10/2010 | 99 |
| Use of nano structured lipid carrier drug feeding system | CN101129335A | Jian et al | 22/9/2010 | 100 |
| Composite anti-screening agent nanostructured lipid carrier and preparation method thereof | CN102688152A | Qiang et al | 26/9/2012 | 101 |
| Lipid nanoparticle capsules | US 2013/0017239 A1 | Petit et al | 17/1/2013 | 102 |
| Bionic lovastatin nano-structured lipid carrier and preparation method thereof | CN102935077A | Jianping et al | 20/2/2013 | 103 |
| Coenzyme Q nanostructured lipid carrier and preparation method thereof | CN101658468A | Summer et al | 6/3/2013 | 104 |
| Nanoparticle formulations for skin delivery | US8715736B2 | Sachdeva et al | 06/05/2014 | 105 |
| A composition for treating leukemia | WO2014123406A1 | Abdullah et al | 14/8/2014 | 106 |
| A method for producing nanolipid formulation for skin care and/or repair and a nanolipid formulation of the same | WO2015105407A1 | Ujang et al | 16/7/2015 | 107 |
| Lipid nanoparticles for wound healing | EP2821077A1 | Lafuente et al | 7/01/2015 | 108 |
| Preparation of nanostructured lipid carriers (NLC) method and products made | CN102283809B | Ismail et al | 14/12/2016 | 109 |
| Nano-structured lipid carrier comprising α-tocopherol and preparing method thereof | KR101777616B1 | Geun et al | 13/9/2017 | 110 |
| Nanostructured carriers for guided and targeted on-demand substance delivery | US Patent Application 20170119891 | Lal et al | 4/5/2017 | 111 |